WO2006125765A3 - Acylated insulin with high purity - Google Patents
Acylated insulin with high purity Download PDFInfo
- Publication number
- WO2006125765A3 WO2006125765A3 PCT/EP2006/062495 EP2006062495W WO2006125765A3 WO 2006125765 A3 WO2006125765 A3 WO 2006125765A3 EP 2006062495 W EP2006062495 W EP 2006062495W WO 2006125765 A3 WO2006125765 A3 WO 2006125765A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- acylated insulin
- high purity
- weight
- acylated
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 7
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention is related to a highly purified pharmaceutical preparation comprising an acylated insulin where the acyl group is attached via a linker molecule to the ϵ- amino group of the B29Lys residue of the parent insulin moiety. The insulin pharmaceutical formulation comprises less than about 3% weight/weight of an isomer of the acylated insulin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06763218A EP1888104A2 (en) | 2005-05-26 | 2006-05-22 | Acylated insulin with high purity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200500767 | 2005-05-26 | ||
DKPA200500767 | 2005-05-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006125765A2 WO2006125765A2 (en) | 2006-11-30 |
WO2006125765A3 true WO2006125765A3 (en) | 2007-02-15 |
Family
ID=37269816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/062495 WO2006125765A2 (en) | 2005-05-26 | 2006-05-22 | Acylated insulin with high purity |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1888104A2 (en) |
WO (1) | WO2006125765A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108026156A (en) | 2015-08-25 | 2018-05-11 | 诺和诺德股份有限公司 | Novel insulin derivates and its medical usage |
US20180244743A1 (en) | 2015-08-25 | 2018-08-30 | Novo Nordisk A/S | Novel Insulin Derivatives and the Medical Uses Hereof |
EP3856141A1 (en) * | 2018-09-25 | 2021-08-04 | Amphastar Pharmaceuticals, Inc. | Highly purified recombinant human insulin (rhi) api and methods of producing the same |
BR112021006315A2 (en) | 2018-10-01 | 2021-07-06 | Boehringer Ingelheim Vetmedica Gmbh | peristaltic pump and analyzer to test a sample |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007931A1 (en) * | 1993-09-17 | 1995-03-23 | Novo Nordisk A/S | Acylated insulin |
WO1999021888A1 (en) * | 1997-10-24 | 1999-05-06 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
US20040138099A1 (en) * | 2002-11-29 | 2004-07-15 | Draeger Eberhard Kurt | Insulin administration regimens for the treatment of subjects with diabetes |
-
2006
- 2006-05-22 WO PCT/EP2006/062495 patent/WO2006125765A2/en not_active Application Discontinuation
- 2006-05-22 EP EP06763218A patent/EP1888104A2/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007931A1 (en) * | 1993-09-17 | 1995-03-23 | Novo Nordisk A/S | Acylated insulin |
EP1132404A2 (en) * | 1993-09-17 | 2001-09-12 | Novo Nordisk A/S | Acylated insulin |
WO1999021888A1 (en) * | 1997-10-24 | 1999-05-06 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
US20040138099A1 (en) * | 2002-11-29 | 2004-07-15 | Draeger Eberhard Kurt | Insulin administration regimens for the treatment of subjects with diabetes |
Also Published As
Publication number | Publication date |
---|---|
WO2006125765A2 (en) | 2006-11-30 |
EP1888104A2 (en) | 2008-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200833326A (en) | Chemical compounds 572 | |
JP2019523228A (en) | Process, pharmaceutical formulation and use thereof for the production of cannabinoid prodrugs | |
WO2006125765A3 (en) | Acylated insulin with high purity | |
Aiello et al. | Clavaminols A–F, novel cytotoxic 2-amino-3-alkanols from the ascidian Clavelina phlegraea | |
US20160297840A1 (en) | Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds | |
WO2008132552A3 (en) | Omega-3 lipid compounds | |
WO2007075838A3 (en) | Pure and stable tiotropium bromide | |
AR048973A1 (en) | (4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL) AMID OF THE ACID 4-HYDROXY-4-METHYL-PIPERIDIN-1-CARBOXYL. PHARMACEUTICAL PREPARATION AND COMPOSITION PROCESS | |
WO2005062985A8 (en) | Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications | |
WO2008012442A3 (en) | Mixture of partial esters of monopentaerythritol, dipentaerythritol and tripentaerythritol, process for obtaining same and cosmetic product containing them | |
SI1831186T1 (en) | A process for the synthesis of valsartan | |
ES2655655T3 (en) | Preparation procedure for alpha-galactosyl ceramide compounds | |
JP4233262B2 (en) | Carbasugar amine derivatives and glycosidase inhibitors using the same | |
WO2008059513A3 (en) | Compounds suitable as modulators of hdl | |
Zamyatina et al. | Synthesis and purity assessment of tetra-and pentaacyl lipid A of Chlamydia containing (R)-3-hydroxyicosanoic acid | |
Washington et al. | Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel | |
UA92833C2 (en) | Pyrazole analogues | |
EP1480647A4 (en) | Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists | |
WO2008049996A3 (en) | Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
GB0208176D0 (en) | Organic compounds | |
CA2273374C (en) | Trioxane dimer compounds having antiproliferative and antitumor activities | |
USRE38117E1 (en) | Trioxane dimer compound having antiproliferative and antitumor activities | |
WO2008053295A3 (en) | Pharmaceutical compositions of benzoquinolizine-2-carboxylic acid | |
Yong et al. | Synthesis of (5R, 8R)-2-(3, 8-Dimethyl-2-oxo-1, 2, 4, 5, 6, 7, 8, 8α-octahydroazulen-5-yl) Acrylic Acid (Rupestonic Acid) Amide Derivatives and in vitro Inhibitive Activities against Influenza A 3, B and Herpes Simplex Type 1 and 2 Virus | |
Bera et al. | Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006763218 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006763218 Country of ref document: EP |